Itch Clinical Trial
Official title:
Effect of Ketamine, Amitriptyline and Their Combination on Histaminergic and Non-histaminergic Itch
Verified date | June 2024 |
Source | Aalborg University |
Contact | Silvia Lo Vecchio |
Phone | +4521397785 |
slv[@]hst.aau.dk | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Chronic itch affects approximately a fifth of the global population and is associated with substantial negative consequences for the affected individuals. Furthermore, there is a lack of efficient treat-ment options for chronic itch. Topical ketamine cream has been used successfully to relieve various forms of pain, and we hypothesize that topical ketamine relieves itch through a mechanism of action comparable to that in pain relief. The aim of this project is to evaluate the effects of ketamine both alone and in combination with amitriptyline on histaminergic and non-histaminergic itch induced by histamine and cowhage, respectively.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Healthy men and women - 18-60 years - Speak and understand English Exclusion Criteria: - Pregnancy or lactation - Drug addiction defined as any use of cannabis, opioids, or other drugs - Previous or current history of neurological, dermatological, immunological, musculoskeletal, cardiac disorder or mental illnesses (psychiatric diagnosis) that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia etc.) - Moles, wounds, scars, or tattoos in the area to be treated or tested - Current use of medications that may affect the trial such as antihistamines and pain killers. - Participants had known allergy/discomfort to ketamine or amitriptyline - Skin diseases - Consumption of alcohol or painkillers 24 hours before the study days and between these - Acute or chronic pain and itch - Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical studies) - Lack of ability to cooperate |
Country | Name | City | State |
---|---|---|---|
Denmark | Silvia Lo Vecchio | Aalborg |
Lead Sponsor | Collaborator |
---|---|
Aalborg University |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measuring itch by computerized Visual Analog Scale Scoring | We will ask the subjects to rate the sensation of itch on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no itch" and 100 indicates "worst itch imaginable". | Immediately after the intervention | |
Primary | Measuring pain by computerized Visual Analog Scale Scoring | We will ask the subjects to rate the sensation of pain on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no pain" and 100 indicates "worst pain imaginable". | Immediately after the intervention | |
Secondary | Superficial blood perfusion | Superficial blood perfusion (SBP) is measured by a Speckle contrast imager | Immediately after the intervention | |
Secondary | Touch Pleasantness | Pleasant touch sensation measured using a standardized sensory brush exerting a force of 200 to 400 mN. | Immediately after the intervention | |
Secondary | Mechanically evoked itch (MEI), intensity approach | MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). | Immediately after the intervention | |
Secondary | Mechanically evoked itch, spatial approach | The von-Frey filament that better evokes the itch sensation during the assessment of mechanically evoked itch as well as a template of soft plastic are used to map the area of hyperkinesis in the test areas (forearms). | Immediately after the intervention | |
Secondary | Mechanical Pain Thresholds (MPT) | This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN. | Immediately after the intervention | |
Secondary | Mechanical Pain Sensitivity (MPS), intensity approach | This test is conducted with the same pinprick set used to test the MPT. | Immediately after the intervention | |
Secondary | Mechanical Pain Sensitivity (MPS), spatial approach | The pinprick that was selected in the MPT as well as a template of soft plastic are used to map the area of hyperalgesia in the test areas (forearms). | Immediately after the intervention | |
Secondary | Cold Detection Thresholds (CDT) | The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device | Immediately after the intervention | |
Secondary | Warm Detection Thresholds (WDT) | The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device | Immediately after the intervention | |
Secondary | Cold Pain Thresholds (CPT) | The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device | Immediately after the intervention | |
Secondary | Heat Pain Thresholds (HPT) | The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device | Immediately after the intervention | |
Secondary | Pain to Supra-threshold Heat Stimuli (STHS) | The tests of thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device | Immediately after the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01683552 -
Aprepitant in the Management of Biological Therapies-related Severe Pruritus
|
Phase 2 | |
Completed |
NCT02075632 -
Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream
|
Phase 2 | |
Completed |
NCT04515056 -
Characterization of New Human Models of Non-histaminergic Itch
|
N/A | |
Completed |
NCT04076865 -
Evaluation of the Effect Induced by Repeated Administration of Topical Local Anaesthetic (EMLA) on Itch
|
N/A | |
Completed |
NCT04588532 -
Characterization of BAM8-22 as a New Surrogate Model of Non-histaminergic Itch
|
N/A | |
Enrolling by invitation |
NCT05195177 -
Testing Protocol to Efficiently Induce Itch
|
N/A | |
Withdrawn |
NCT03943407 -
Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% as a New Surrogate Model of Itch
|
N/A | |
Completed |
NCT04858360 -
Inhibition of Non-histaminergic Pruritus Applied Using 3 Different Pruritogens
|
N/A | |
Completed |
NCT04635254 -
The Effect of Halophyte-based Cream on Pain and Itch
|
N/A | |
Not yet recruiting |
NCT06201715 -
Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis
|
N/A | |
Completed |
NCT06036589 -
Characterization of Bovine Adrenal Medulla as a Model of Non-histaminergic Itch
|
N/A | |
Completed |
NCT04554888 -
Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor
|
N/A | |
Completed |
NCT04387851 -
Learning Mechanisms for Placebo and Nocebo Studies on Somatosensory Sensations: a Systematic Review and Meta-analysis.
|
||
Completed |
NCT03928223 -
The Color of Itch; Itch Modification by Color Viewing
|
||
Completed |
NCT03576053 -
A Mechanistic Evaluation of the Interactions Between Thermoceptive and Pruriceptive Sensory Processing
|
N/A | |
Completed |
NCT04700007 -
Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine (Second Sub-Project)
|
N/A | |
Terminated |
NCT02828787 -
Central Mechanisms of Chronic Pruritus: Functional and Structural Brain Imaging.
|
N/A | |
Not yet recruiting |
NCT04197440 -
Characterization of Bovine Adrenal Medulla (BAM8-22) as a New Surrogate Model of Non-histaminergic Itch
|
N/A | |
Completed |
NCT04115462 -
A Relation of Morphine-induced Itch and Pain Processing
|
N/A | |
Completed |
NCT05249387 -
Characterization of Bovine Adrenal Medulla as a New Surrogate Model of Non-histaminergic Itch
|
N/A |